About
My research area is mainly focused on the use of preclinical mouse models to evaluate the efficacy of new molecular imaging probes. It includes identifying key molecular targets in pathologies and design imaging tools to monitor their expression. Planning of related experiments and development of models to quantify a given physiological process constitutes my major interest. I defended my PhD entitled “Development of a molecular and a nanoparticle targeting of vascular dysfunctions” at the end of the year 2022. During my PhD, I mainly focused on the diagnosis part with an open perspective on theranostics. My PhD research led to the design of a new probe, AP747. This innovative tool can be used for both imaging and therapy purposes in cardiovascular and oncologic applications. In parallel to this, a nano-object (dendrimers) was further optimized and functionalized as an imaging tool for the quantification of the EPR effect. I started my postdoctoral position in the Department of Molecular & Medical Pharmacology started in 2023 in the Ahmanson Translational Theranostics Division . My work here is centered around radioligand therapy (225Ac, 177Lu). I mainly focus on prostate cancer, especially Metastatic Castration-Resistant Prostate Cancer (mCRPC) and on potential combinations between radioligand therapy based on PSMA and immunotherapies. Regarding my future career plans, I want to specialize myself in theranostics and build my career in this field.